Clinical Trials Logo

Thymus Neoplasms clinical trials

View clinical trials related to Thymus Neoplasms.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06402708 Recruiting - Thymic Carcinoma Clinical Trials

Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)

Start date: April 9, 2024
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to learn the role of adjuvant chemotherapy for patients with thymic carcinoma and completed resection. The main questions it aims to answer are: 1. Does adjuvant chemotherapy decrease disease progression? 2. Does medium dose of three drugs (paclitaxel, cisplatin, 5-FU) well tolerance? Researchers will compare chemoradiotherapy to radiotherapy to see whether chemoradiotherapy could decrease disease progression or not. Participants will: 1. Take radiotherapy (50Gy/25f) with or without 4 cycles of chemotherapy (TPF). 2. Follow up every 3 months in the first two year, and then every 6 months.

NCT ID: NCT06301945 Recruiting - Thymoma Clinical Trials

Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors

INTHYM
Start date: August 1, 2023
Phase:
Study type: Observational

Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and/or more aggressive subtypes, defined by the WHO histopathological classification. In this classification thymoma types A, AB, B1, B2, B3, and thymic carcinoma are distinguished. Studies have shown large discordances between pathologists in subtyping these tumors. Moreover, the WHO classification alone does not accurately predict the risk of recurrence, as within subtypes patients have divergent prognoses. The investigators will develop AI models using digital pathology and relevant clinical variables to improve the accuracy of histopathological classification of thymic epithelial tumors, and to better predict the risk of recurrence. In this multicentric and international project three existing databases will be used from Rotterdam, Maastricht and Lyon. For all models one database will be used to build AI models, and the other two for external validation. The ultimate goal of this project is to develop AI models that support the pathologist in correctly subtyping thymic epithelial tumors, in order to prevent patients from under- or overtreatment with adjuvant radiotherapy.

NCT ID: NCT06248515 Recruiting - Thymoma Clinical Trials

A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

Start date: April 25, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to study the effect of sacituzumab govitecan-hziy in adult patients with advanced thymoma and thymic carcinoma after progressing on at least one prior line of therapy. The main question it aims to answer is: • What is the overall response rate (ORR) in patients with advanced thymoma and thymic carcinoma? Participants will: - receive a fixed dose of 10 mg/kg given intravenously, once weekly on Days 1 and 8 of continuous 21-day treatment cycles until disease progression or unacceptable toxicity - have regular blood tests, scans, and examinations to monitor their health. - have blood and a biopsy of their tumor for research purposes.

NCT ID: NCT06189183 Recruiting - Thymus Neoplasms Clinical Trials

Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection

Start date: November 11, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficiency and toxicity of adjuvant hypofractionation radiotherapy for thymic epithelial tumours after complete resection.

NCT ID: NCT06086327 Recruiting - Thymoma Clinical Trials

Application of 68Ga-Pentixafor PET/CT for Thymoma

Start date: June 22, 2023
Phase: Early Phase 1
Study type: Interventional

Chemokine receptor CXCR4 was expressed in T cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of thymoma with higher accuracy. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, distinguish evaluation for thymoma.

NCT ID: NCT06029621 Recruiting - Thymoma Clinical Trials

Robot-assisted vs VATS for Thymoma

Start date: November 20, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to explore the advantages of robot-assisted thymectomy in long-term survival benefits and short-term clinical efficacy compared with video-assisted thoracoscopic thymectomy based on a multi-center, prospective, randomized controlled clinical trial.

NCT ID: NCT06019468 Recruiting - Thymic Carcinoma Clinical Trials

Neoadjuvant Treatment For Locally Advanced Thymic Cancer

Start date: September 4, 2023
Phase: Phase 2
Study type: Interventional

The aims of this study are to verify the feasibility, effectiveness, and safety of the combination of enrolizumab and radiotherapy for neoadjuvant treatment for locally advanced thymic carcinoma, and to provide recommendations for the establishment of unified evaluation criteria for the neoadjuvant therapy of thymic cancer by evaluating the pathological remission status of thymic cancer specimens after neoadjuvant treatment.

NCT ID: NCT05918302 Recruiting - Clinical trials for Neuroendocrine Tumors

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

LEVEL
Start date: October 27, 2023
Phase: Phase 3
Study type: Interventional

LEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy. It is hypothesized that 177Lu-edotreotide may significantly increase the progression-free survival (PFS) compared to everolimus in lung and thymic carcinoids.

NCT ID: NCT05683886 Recruiting - Thymic Tumors Clinical Trials

A Study of KC1036 in Patients With Advanced Thymic Tumors

Start date: February 22, 2023
Phase: Phase 2
Study type: Interventional

This is a single arm,open-label, multicentric, phase II study to evaluate the efficacy and safety of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma.

NCT ID: NCT05667948 Recruiting - Thymic Carcinoma Clinical Trials

Molecular Analysis and Treatment Options of Thymic Malignancies

Start date: January 1, 2016
Phase:
Study type: Observational

Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death. Therefore, there is an unmet need for more effective therapies for thymic malignancies. Considering the role of molecular alterations has yet to be defined in the treatment of thymoma and thymic malignancies, there is an urgent recognition that molecular alterations in the thymic malignancies are important to predict response and survival for novel targeted therapies. In summary, identification of genetic alterations in thymic malignancies is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with thymic malignancies to further the characterization of molecular alterations and develop (novel) treatments based on the detection.